ReviewFluorescence in Situ Hybridization Study of HER-2/neu Oncogene Amplification in Prostate Cancer☆
References (32)
- et al.
FISH assessment of chromosome 8 copy number in Stage I and Stage II infiltrating ductal carcinoma of the breast
Cancer Genet. Cytogenet
(1997) - et al.
The value of screening tests in the detection of prostate cancer. Part I. Results of a retrospective evaluation of 1726 men
Urology
(1995) The neu-oncogene: More than a prognostic indicator
Hum. Pathol.
(1994)- et al.
Expression of the c-erb B-2 (HER-2/neu) oncoprotein in human prostatic carcinoma
J. Urol.
(1993) - et al.
A subset of gestational trophoblastic disease characterized by abnormal chromosome 8 copy number detected by fluorescence in situ hybridization
Cancer Genet. Cytogenet.
(1997) - et al.
Overexpression of HER-2/neu may be an indicator of poor prognosis in prostate cancer
J. Urol.
(1993) - et al.
Fluorescent in situ hybridization assessment of chromosome 8 copy number in breast cancer
Breast Cancer Res. Treatment
(1996) - et al.
HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
J. Clin. Oncol.
(1992) - et al.
Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior
Am. J. Clin. Pathol.
(1994) The molecular pathology of colorectal and mammary carcinoma: Prognostic and therapeutic implications for surgeons
Ann. Surg.
(1995)
Oncogene protein co-expression: Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma
Ann. Surg.
Diagnosis and staging of prostate cancer
Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry
N. Engl. J. Med.
C-erb B-2 oncogene overexpression in uterine cervix carcinoma with glandular differentiation
Am. J. Clin. Pathol.
Gene amplification in advanced-stage human prostate cancer
Urol. Res.
Cited by (51)
The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma
2023, Annals of Diagnostic PathologyMatriptase is involved in ErbB-2-induced prostate cancer cell invasion
2010, American Journal of PathologyCitation Excerpt :A similar result was also found by Osman et al.6 Together, this suggests that the protein level of ErbB-2 could be elevated in a subgroup of recurrent, hormone-refractory prostate cancer. In prostate tumor tissue, the results from the chromogenic in situ hybridization showed that ErbB-2 gene is not amplified, as reported by several groups.8,63–66 Thus, it is clear that ErbB-2 gene is not amplified in prostate carcinomas although the protein level may be elevated in a subgroup of patients, especially with metastasis.6,8
Molecular markers of prostate cancer outcome
2005, European Journal of CancerGenetic alterations in prostate cancer
2005, Clinical Prostate CancerMolecular markers and prostate cancer prognosis
2004, Clinical Prostate Cancer
- ☆
We thank Dr. Roger Mark for reading the manuscript. The support of the staff at the Lifespan Academic Medical Center Cytogenetics Laboratory is also acknowledged. This project was supported in part by Vysis (Downers Grove, IL).